<DOC>
	<DOCNO>NCT00136643</DOCNO>
	<brief_summary>The objective clinical study evaluate extend safety , tolerance acceptability vaginal gel formulation apply 452 healthy woman volunteer . This vaginal formulation show well tolerate previous small clinical study . The formulation develop microbicide prevention sexually transmit infection ( STIs ) include HIV .</brief_summary>
	<brief_title>Safety , Tolerance Acceptability Trial Invisible CondomÂ® Healthy Women</brief_title>
	<detailed_description>Objectives : The objective Phase I/II clinical trial evaluate safety , tolerance acceptability gel formulation contain sodium lauryl sulfate ( SLS ) ( compare gel alone placebo ) apply intravaginally healthy volunteer . Design : In part A protocol , three group : gel alone , gel plus SLS , placebo test safety , tolerance acceptability apply intravaginally , twice three time daily 14 day 252 healthy subject . The volunteer divide follow : 36 sexually abstinent healthy subject ( 12 per group ) apply gel , gel plus SLS placebo daily 14 day ; 72 sexually active healthy subject ( 24 per group ) apply gel , gel plus SLS placebo daily 14 day ; 72 sexually active healthy subject ( 24 per group ) apply gel , gel plus SLS placebo twice daily 14 day 72 sexually active healthy subject ( 24 per group ) apply gel , gel plus SLS placebo three time daily 14 day . The gel apply menses . For sexually active group , gel apply less 1 hour sexual intercourse , plan . Subjects vaginal intercourse minimum 4 time 2-week period gel application . In part B protocol , extend safety gel alone , gel plus SLS placebo study apply intravaginally twice daily 8 week sexually active healthy subject . In part B ( actually represent Phase II trial ) , 80 healthy sexually active subject gel alone group 80 subject gel + SLS group 40 subject placebo group , study . The part B involve participation total 200 subject . Subjects vaginal intercourse minimum 4 time 2-week period gel application . The gel apply menses . The gel apply less 1 hour sexual intercourse , plan , twice day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<criteria>Sign inform consent Healthy female subject age 18 49 . Healthy female subject define individual free clinically significant illness disease determine medical history , physical examination laboratory test . Normal physical gynecological examination Normal colposcopic examination Have regular menstrual cycle 2140 day menses HIVnegative subject low risk acquire HIV At low risk get STIs ( i.e . sexually abstinent history protect sexual intercourse stable sexual partner ) . Sexual intercourse define vaginal penetration . Stable sexual partner define sexual partner length study . Agreeing abstain sexual intercourse screen end study ( sexually abstinent subject ) . Agreeing sexual intercourse minimum 4 time period two week gel application ( sexually active subject ) Clinically significant abnormal physical and/or gynecological examination Clinically significant abnormal laboratory finding Allergy applicator material ( polyethylene ) gel polymer ( polyoxyethylenepolyoxypropylene ) latex Participation investigational study involve drug , vaccine microbicides last 30 day History toxic shock syndrome HIV infection Bacterial vaginosis Candida Trichomonas vaginitis time screen STIs ( gonorrhea , chlamydia , syphilis , genital herpes , chancroid ) time screen Breakthrough menstrual bleeding , vaginal bleeding follow sexual intercourse , last 3 month Intravenous ( IV ) drug use except medical reason last year Pregnant enrolment breastfeed Having receive antibiotic last 14 day Subjects consider unreliable unable understand follow study protocol direction Use intrauterine device</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>microbicide</keyword>
	<keyword>Women</keyword>
	<keyword>Prevention</keyword>
	<keyword>HIV</keyword>
	<keyword>STIs</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>prevention sexually transmit infection include HIV .</keyword>
</DOC>